Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    editors, Athanasios D. Gouliamos, John A. Andreou and Paris A. Kosmi.
    Summary: Designed to promote teamwork between radiologists and clinical oncologists, this book covers the currently available imaging modalities of relevance in clinical oncology. Discusses and illustrates a broad spectrum of oncologic diseases on these modalities.

    Contents:
    Intro; Foreword; Preface; Acknowledgments; Contents; Part I: Introductory;
    1: Molecular Imaging in Oncology: Hybrid Imaging and Personalized Therapy of Cancer; 1.1 Introduction; 1.1.1 Molecular Imaging: The Principle and Its Historical Development; 1.2 General Methods of Molecular Imaging; 1.2.1 External Probes; 1.2.2 Internal Probes; 1.3 Clinical Applications of Molecular Imaging; 1.3.1 Traditional Clinical Applications of MI; 1.3.2 Current Clinical Applications of MI; Contemporary Hybrid Imaging of Cancer; 1.3.3 Personalized Therapy of Cancer [5]; Cancer as a Genomic Problem Current Therapeutic Issues of CancerPersonalized Cancer Therapy (PCT); Personalized Cancer Therapy Requirements; Tasks for Molecular and Hybrid Imaging; Current Experience in Applying PCT; Current Specific Studies in Applying PCT; Future Directions; References;
    2: Imaging Criteria for Tumor Treatment Response Evaluation; 2.1 The Response Evaluation Criteria of the World Health Organization; 2.2 The Response Evaluation Criteria in Solid Tumors; 2.3 The Revision 1.1 of RECIST [3]; 2.3.1 Aim of Guideline RECIST 1.1; 2.3.2 Assessment of Measurable Tumor Burden 2.3.3 Evaluation of Response to Therapy [3, 6-8]2.3.4 Evaluation of the Response of "Target Lesions"; 2.3.5 Evaluation of the Response of "Non-target" Lesions; 2.3.6 Evaluation of New Lesions; 2.3.7 Assessment of the Best Overall Response; 2.3.8 Recommendations and Guidelines for Performing Imaging Examinations; 2.3.8.1 Computed Tomography (CT); 2.3.8.2 Magnetic Resonance Imaging (MRI); 2.3.8.3 Ultrasonography (US); 2.3.8.4 Positron Emission Tomography (PET); 2.3.9 Limitations of RECIST 1.1; References;
    3: Imaging in Radiation Therapy; 3.1 Introduction 3.2 Pre-treatment Evaluation3.3 Treatment Planning; 3.4 Image-Guided Radiation Therapy: Adaptive Radiotherapy; 3.5 The MR-Linac; 3.6 Post-treatment Outcome Evaluation; 3.7 Future Trends: Functional Image-Guided Dose Optimization or Dose Painting; References;
    4: Interventional Radiology in Oncology; 4.1 Thermal Tumor Ablation; 4.1.1 Radiofrequency Ablation (RFA); 4.1.2 Microwave Ablation (MWA); 4.1.3 Cryoablation; 4.2 Liver Tumors; 4.2.1 Hepatocellular Carcinoma (HCC); 4.2.1.1 Complications; 4.2.1.2 Side Effects; 4.2.2 Liver Metastases; 4.2.3 Thermal Ablation of Renal Tumors 4.2.4 Thermal Ablation of Lung Tumors4.3 Irreversible Electroporation (IRE); 4.3.1 Chemoembolization; 4.3.1.1 Chemoembolization (Conventional TACE; c-TACE); 4.3.1.2 Embolization (Bland Embolization); 4.3.1.3 Drug-Eluting Bead Chemoembolization; 4.3.1.4 Common Considerations for Chemoembolization; 4.3.1.5 Results; 4.3.2 Radioembolization; 4.4 Palliative Procedures; 4.4.1 Indications for Esophageal Stent; 4.4.2 Percutaneous Biliary Drainage (PTBD) and Stent Insertion; 4.4.3 Percutaneous Nephrostomy and Ureteral Stent Insertion; 4.5 Biopsy; References
    Digital Access Springer 2018
  • Article
    Zimmerman CJ, Izumi M, Larsen PR.
    Metabolism. 1978 Mar;27(3):303-13.
    A method for the isolation of small quantities of labeled 3,5,3' -triiodothyronine (T3) from serum or thyroid extracts is described. Conjugates of rabbit anti-T3 antibody to Sepharose 4B are incubated with 0.5 to 1 ml of human or rat serum at pH 8.6 for 1 hr. The tubes are centrifuged and washed with buffer followed by 6 M guanidine to remove nonspecifically bound labeled thyroxine (T4). The fraction of T3 and T4 bound to the Sepharose conjugate varies depending on the concentration of serum in the initial incubation tubes, the T3 and T4 content, and the specificity of the antiserum used. In a system that contains 0.5 ml of normal human serum, 1 ml of glycine-acetate buffer (pH 8.6), and 0.25 ml settled Sepharose-anti-T3 conjugate, the T3 to T4 binding ratio was generally 150-200, with up to as much as 50% of T3 bound to the pellet. The coefficient of variation of the method is less than 5%, and it may be performed in a matter of hours. There is no detectable conversion of T4 to T3 during the separation process. Using this technique, conversion of T4 to T3 was evaluated in euthyroid rats after injection of 125l-T4. Over the period of 36-72 hr after injection, a ratio of T3 to T4 of 0.74 +- 0.06 x 10-2 (mean +- SE) was present in the plasma. Using the calculated metabolic clearance rates for T3 and T4 in these animals, fractional conversion of T4 to T3 was estimated to be 27%, in good agreement with results obtained by other techniques. This method would appear to be of value for specific isolation of the small quantities of T3 produced from T4 after in vivo or in vitro T4 to T3 conversion.
    Digital Access Access Options